AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33
RISK-FACTORS IN BONE-MARROW TRANSPLANT RECIPIENTS WITH LEUKEMIA - INCREASED RELAPSE RISK IN PATIENTS TREATED WITH CIPROFLOXACIN FOR GUT DECONTAMINATION
Authors: CARLENS S RINGDEN O ASCHAN J HAGGLUND H LJUNGMAN P MATTSSON J REMBERGER M
Citation: S. Carlens et al., RISK-FACTORS IN BONE-MARROW TRANSPLANT RECIPIENTS WITH LEUKEMIA - INCREASED RELAPSE RISK IN PATIENTS TREATED WITH CIPROFLOXACIN FOR GUT DECONTAMINATION, Clinical transplantation, 12(2), 1998, pp. 84-92
RISK-FACTORS FOR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER BONE-MARROW TRANSPLANTATION - A RETROSPECTIVE SINGLE-CENTER ANALYSIS
Authors: CARLENS S RINGDEN O REMBERGER M LONNQVIST B HAGGLUND H KLAESSON S MATTSSON J SVAHN BM WINIARSKI J LJUNGMAN P ASCHAN J
Citation: S. Carlens et al., RISK-FACTORS FOR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER BONE-MARROW TRANSPLANTATION - A RETROSPECTIVE SINGLE-CENTER ANALYSIS, Bone marrow transplantation, 22(8), 1998, pp. 755-761
BOOSTER MARROW OR BLOOD-CELLS FOR GRAFT FAILURE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: REMBERGER M RINGDEN O LJUNGMAN P HAGGLUND H WINIARSKI J LONNQVIST B ASCHAN J
Citation: M. Remberger et al., BOOSTER MARROW OR BLOOD-CELLS FOR GRAFT FAILURE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Bone marrow transplantation, 22(1), 1998, pp. 73-78
TRANSPLANTATION WITH UNRELATED BONE-MARROW IN LEUKEMIC PATIENTS ABOVE40 YEARS OF AGE
Authors: RINGDEN O REMBERGER M MATTSSON J ASCHAN J CARLENS S HAGGLUND H LONNQVIST B SPARRELID E LJUNGMAN P
Citation: O. Ringden et al., TRANSPLANTATION WITH UNRELATED BONE-MARROW IN LEUKEMIC PATIENTS ABOVE40 YEARS OF AGE, Bone marrow transplantation, 21(1), 1998, pp. 43-49
LOW INCIDENCE OF ACUTE GRAFT-VERSUS-HOST DISEASE, USING UNRELATED HLA-A, HLA-B, AND HLA-DR IDENTICAL DONORS AND CONDITIONING, INCLUDING ANTI-T-CELL ANTIBODIES
Authors: RINGDEN O REMBERGER M CARLENS S HAGGLUND H MATTSSON J ASCHAN J LONNQVIST B KLAESSON S WINIARSKI J DALIANIS T OLERUP O SPARRELID E LJUNGMAN P
Citation: O. Ringden et al., LOW INCIDENCE OF ACUTE GRAFT-VERSUS-HOST DISEASE, USING UNRELATED HLA-A, HLA-B, AND HLA-DR IDENTICAL DONORS AND CONDITIONING, INCLUDING ANTI-T-CELL ANTIBODIES, Bone marrow transplantation, 21, 1998, pp. 114-114
BILATERAL SUBDURAL HEMATOMAS FOLLOWING INTRATHECAL INJECTION IN 3 BONE-MARROW TRANSPLANT RECIPIENTS
Authors: HENTSCHKE P HAGGLUND H MATTSSON J CARLENS S LONNQVIST B LJUNGMAN P ASCHAN J RINGDEN O
Citation: P. Hentschke et al., BILATERAL SUBDURAL HEMATOMAS FOLLOWING INTRATHECAL INJECTION IN 3 BONE-MARROW TRANSPLANT RECIPIENTS, Bone marrow transplantation, 21, 1998, pp. 326-326
PUVA TREATMENT FOR GRAFT-VERSUS-HOST DISEASE - A RETROSPECTIVE ANALYSIS
Authors: ASCHAN J EMTESTAM L LJUNGMAN P LONNQVIST B RINGDEN O
Citation: J. Aschan et al., PUVA TREATMENT FOR GRAFT-VERSUS-HOST DISEASE - A RETROSPECTIVE ANALYSIS, Bone marrow transplantation, 21, 1998, pp. 395-395
LOW-DOSE CYCLOSPORINE PROPHYLAXIS DOES NOT INCREASE THE RISK OF SEVERE ACUTE GVHD IN HLA-IDENTICAL SIBLING MARROW TRANSPLANT RECIPIENTS WITH LEUKEMIA
Authors: CARLENS S ASCHAN J REMBERGER M RINGDEN O
Citation: S. Carlens et al., LOW-DOSE CYCLOSPORINE PROPHYLAXIS DOES NOT INCREASE THE RISK OF SEVERE ACUTE GVHD IN HLA-IDENTICAL SIBLING MARROW TRANSPLANT RECIPIENTS WITH LEUKEMIA, Bone marrow transplantation, 21, 1998, pp. 414-414
LOW INCIDENCE OF ACUTE GRAFT-VERSUS-HOST DISEASE, USING UNRELATED HLA-A-COMPATIBLE, HLA-B-COMPATIBLE, AND HLA-DR-COMPATIBLE DONORS AND CONDITIONING, INCLUDING, ANTI-T-CELL ANTIBODIES
Authors: RINGDEN O REMBERGER M CARLENS S HAGGLUND H MATTSSON J ASCHAN J LONNQVIST B KLAESSON S WINIARSKI J DALIANIS T OLERUP O SPARRELID E ELMHORNROSENBORG A SVAHN BM LJUNGMAN P
Citation: O. Ringden et al., LOW INCIDENCE OF ACUTE GRAFT-VERSUS-HOST DISEASE, USING UNRELATED HLA-A-COMPATIBLE, HLA-B-COMPATIBLE, AND HLA-DR-COMPATIBLE DONORS AND CONDITIONING, INCLUDING, ANTI-T-CELL ANTIBODIES, Transplantation, 66(5), 1998, pp. 620-625
TRANSPLANTATION WITH UNRELATED BONE-MARROW IN LEUKEMIC PATIENTS ABOVE40 YEARS OF AGE
Authors: RINGDEN P REMBERGER M MATTSSON J ASCHAN J HAGGLUND H LONNQVIST B SPARRELID E LJUNGMAN P
Citation: P. Ringden et al., TRANSPLANTATION WITH UNRELATED BONE-MARROW IN LEUKEMIC PATIENTS ABOVE40 YEARS OF AGE, Experimental hematology, 25(8), 1997, pp. 33-33
RIBAVIRIN THERAPY IN BONE-MARROW TRANSPLANT RECIPIENTS WITH VIRAL RESPIRATORY-TRACT INFECTIONS
Authors: SPARRELID E LJUNGMAN P EKELOFANDSTROM E ASCHAN J RINGDEN O WINIARSKI J WAHLIN B ANDERSSON J
Citation: E. Sparrelid et al., RIBAVIRIN THERAPY IN BONE-MARROW TRANSPLANT RECIPIENTS WITH VIRAL RESPIRATORY-TRACT INFECTIONS, Bone marrow transplantation, 19(9), 1997, pp. 905-908
TRANSPLANTATION WITH UNRELATED BONE-MARROW IN LEUKEMIC PATIENTS ABOVE40 YEARS OF AGE
Authors: RINGDEN O REMBERGER M MATTSSON J ASCHAN J HAGGLUND H CARLENS S LONNQVIST B SPARRELID E LJUNGMAN P
Citation: O. Ringden et al., TRANSPLANTATION WITH UNRELATED BONE-MARROW IN LEUKEMIC PATIENTS ABOVE40 YEARS OF AGE, Transplantation proceedings, 29(7), 1997, pp. 3145-3146
FACTORS AFFECTING RISK OF RELAPSE AND LEUKEMIA-FREE SURVIVAL IN HLA-IDENTICAL SIBLING MARROW TRANSPLANT RECIPIENTS WITH LEUKEMIA
Authors: CARLENS S RINGDEN O REMBERGER M MATTSSON J ASCHAN J HAGGLUND H LJUNGMAN P
Citation: S. Carlens et al., FACTORS AFFECTING RISK OF RELAPSE AND LEUKEMIA-FREE SURVIVAL IN HLA-IDENTICAL SIBLING MARROW TRANSPLANT RECIPIENTS WITH LEUKEMIA, Transplantation proceedings, 29(7), 1997, pp. 3147-3149
A LOW INCIDENCE OF GRADE-II TO GRADE-IV ACUTE GVHD, BUT HIGH MORTALITY FROM, INFECTION USING HLA-A, HLA-B, AND HLA-DR-IDENTICAL UNRELATED DONORS AND IMMUNOSUPPRESSION WITH ATG, CYCLOSPORINE, AND METHOTREXATE
Authors: MATTSSON J RINGDEN O ASCHAN J BARKHOLT L DALIANIS T HAGGLUND H LJUNGMAN P LONNQVIST B TOLLEMAR J WINIARSKI J REMBERGER M
Citation: J. Mattsson et al., A LOW INCIDENCE OF GRADE-II TO GRADE-IV ACUTE GVHD, BUT HIGH MORTALITY FROM, INFECTION USING HLA-A, HLA-B, AND HLA-DR-IDENTICAL UNRELATED DONORS AND IMMUNOSUPPRESSION WITH ATG, CYCLOSPORINE, AND METHOTREXATE, Transplantation proceedings, 29(1-2), 1997, pp. 735-736
ORAL RIBAVIRIN FOR PREVENTION OF SEVERE LIVER-DISEASE CAUSED BY HEPATITIS-C VIRUS DURING ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: LJUNGMAN P ANDERSSON J ASCHAN J BJORKSTRAND B HAGGLUND H LONNQVIST B RINGDEN O WINIARSKI J
Citation: P. Ljungman et al., ORAL RIBAVIRIN FOR PREVENTION OF SEVERE LIVER-DISEASE CAUSED BY HEPATITIS-C VIRUS DURING ALLOGENEIC BONE-MARROW TRANSPLANTATION, Clinical infectious diseases, 23(1), 1996, pp. 167-169
FOSCARNET FOR PREEMPTIVE THERAPY OF CMV INFECTION DETECTED BY A LEUKOCYTE-BASED NESTED PCR IN ALLOGENEIC BONE-MARROW TRANSPLANT PATIENTS
Authors: LJUNGMAN P OBERG G ASCHAN J EHRNST A LONNQVIST B PAUKSEN K SULILA P
Citation: P. Ljungman et al., FOSCARNET FOR PREEMPTIVE THERAPY OF CMV INFECTION DETECTED BY A LEUKOCYTE-BASED NESTED PCR IN ALLOGENEIC BONE-MARROW TRANSPLANT PATIENTS, Bone marrow transplantation, 18(3), 1996, pp. 565-568
USE OF A SEMIQUANTITATIVE PCR FOR CYTOMEGALOVIRUS DNA AS A BASIS FOR PREEMPTIVE ANTIVIRAL THERAPY IN ALLOGENEIC BONE-MARROW TRANSPLANT PATIENTS
Authors: LJUNGMAN P LORE K ASCHAN J KLAESSON S LEWENSOHNFUCHS I LONNQVIST B RINGDEN O WINIARSKI J EHRNST A
Citation: P. Ljungman et al., USE OF A SEMIQUANTITATIVE PCR FOR CYTOMEGALOVIRUS DNA AS A BASIS FOR PREEMPTIVE ANTIVIRAL THERAPY IN ALLOGENEIC BONE-MARROW TRANSPLANT PATIENTS, Bone marrow transplantation, 17(4), 1996, pp. 583-587
GRAFT-VERSUS-MYELOMA EFFECT
Authors: ASCHAN J LONNQVIST B RINGDEN O KUMLIEN G GAHRTON G
Citation: J. Aschan et al., GRAFT-VERSUS-MYELOMA EFFECT, Lancet, 348(9023), 1996, pp. 346-346
SIMILAR INCIDENCE OF GRAFT-VERSUS-HOST DISEASE USING HLA-A, HLA-B ANDHLA-DR IDENTICAL UNRELATED BONE-MARROW DONORS AS WITH HLA-IDENTICAL SIBLINGS
Authors: RINGDEN O REMBERGER M PERSSON U LJUNGMAN P ALDENER A ANDSTROM E ASCHAN J BOLME P DAHLLOF G DALIANIS T GAHRTON G HAGGLUND H LONNQVIST B OLERUP O SHANWELL A SPARRELID E WINIARSKI J MOLLER E OBERG M
Citation: O. Ringden et al., SIMILAR INCIDENCE OF GRAFT-VERSUS-HOST DISEASE USING HLA-A, HLA-B ANDHLA-DR IDENTICAL UNRELATED BONE-MARROW DONORS AS WITH HLA-IDENTICAL SIBLINGS, Bone marrow transplantation, 15(4), 1995, pp. 619-625
BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA USING UNRELATED DONORS - THE EXPERIENCE AT HUDDINGE-HOSPITAL
Authors: ASCHAN J RINGDEN O LJUNGMAN P HAGGLUND H KLAESSON S DALIANIS T REMBERGER M
Citation: J. Aschan et al., BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA USING UNRELATED DONORS - THE EXPERIENCE AT HUDDINGE-HOSPITAL, Transplantation proceedings, 27(6), 1995, pp. 3531-3532
DOES HIGH-DOSE INTRAVENOUS IMMUNE GLOBULIN TREATMENT AFTER BONE-MARROW TRANSPLANTATION INCREASE MORTALITY IN VENOOCCLUSIVE DISEASE OF THE LIVER
Authors: KLAESSON S RINGDEN O LJUNGMAN P ASCHAN J HAGGLUND H WINIARSKI J
Citation: S. Klaesson et al., DOES HIGH-DOSE INTRAVENOUS IMMUNE GLOBULIN TREATMENT AFTER BONE-MARROW TRANSPLANTATION INCREASE MORTALITY IN VENOOCCLUSIVE DISEASE OF THE LIVER, Transplantation, 60(11), 1995, pp. 1225-1230
LONG-TERM EFFECTS OF HEPATITIS-C VIRUS-INFECTION IN ALLOGENEIC BONE-MARROW TRANSPLANT RECIPIENTS
Authors: LJUNGMAN P JOHANSSON N ASCHAN J GLAUMANN H LONNQVIST B RINGDEN O SPARRELID E SONNERBORG A WINIARSKI J GAHRTON G
Citation: P. Ljungman et al., LONG-TERM EFFECTS OF HEPATITIS-C VIRUS-INFECTION IN ALLOGENEIC BONE-MARROW TRANSPLANT RECIPIENTS, Blood, 86(4), 1995, pp. 1614-1618
PROGNOSTIC FACTORS FOR LONG-TERM SURVIVAL IN LEUKEMIC MARROW RECIPIENTS WITH SPECIAL EMPHASIS ON AGE AND PROPHYLAXIS FOR GRAFT-VERSUS-HOST DISEASE
Authors: ASCHAN J RINGDEN O
Citation: J. Aschan et O. Ringden, PROGNOSTIC FACTORS FOR LONG-TERM SURVIVAL IN LEUKEMIC MARROW RECIPIENTS WITH SPECIAL EMPHASIS ON AGE AND PROPHYLAXIS FOR GRAFT-VERSUS-HOST DISEASE, Clinical transplantation, 8(3), 1994, pp. 258-270
TREATMENT OF MODERATE TO SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE - A RETROSPECTIVE ANALYSIS
Authors: ASCHAN J
Citation: J. Aschan, TREATMENT OF MODERATE TO SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE - A RETROSPECTIVE ANALYSIS, Bone marrow transplantation, 14(4), 1994, pp. 601-607
INDIVIDUALIZED PROPHYLAXIS AGAINST GRAFT-VERSUS-HOST DISEASE IN LEUKEMIC MARROW TRANSPLANT RECIPIENTS
Authors: ASCHAN J RINGDEN O ANDSTROM E LJUNGMAN P LONNQVIST B REMBERGER M
Citation: J. Aschan et al., INDIVIDUALIZED PROPHYLAXIS AGAINST GRAFT-VERSUS-HOST DISEASE IN LEUKEMIC MARROW TRANSPLANT RECIPIENTS, Bone marrow transplantation, 14(1), 1994, pp. 79-87
Risultati: 1-25 | 26-33